Cranbury, NJ – According to filings with the U.S. Securities and Exchange Commission, Outlook Therapeutics is raising $7,971,155.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Lawrence Kenyon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Outlook Therapeutics

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications. Our goal is to launch LYTENAVA as the first and only approved ophthalmic formulation of bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).

To learn more about Outlook Therapeutics, visit http://outlooktherapeutics.com/

Contact:
Lawrence Kenyon, Chief Executive Officer
609-619-3990
lawrencekenyon@outlooktherapeutics.com
https://www.linkedin.com/in/lawrencekenyon/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved